S0317, Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

This study is ongoing, but not recruiting participants.

Study NCT00060307 Information provided by Southwest Oncology Group

First Received: May 6, 2003 Last Updated: July 21, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Pan C, Hussey M, Lara PN, et al.: Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): final results from Southwest Oncology Group study 0317. [Abstract] J Clin Oncol 26 (Suppl 15): A-5051, 2008.

Pan C, Hussey M, Lara P, et al.: Phase II trial of the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in patients (pts) with advanced papillary renal cell carcinoma (pRCC): SWOG S0317. [Abstract] J Clin Oncol 25 (Suppl 18): A-15516, 651s, 2007.